Modifications in Coagulation Parameters Induced by Treatment Associating Urokinase (2000 u CTA/kg/h) with Heparin

Summary

Twenty-nine patients with deep venous thrombosis of the lower limbs were treated for 48 hours by intravenous infusion of urokinase (2000 u CTA/kg/h) and heparin (5 mg/kg/24 h).

Plasma coagulation parameters were measured every 12 hours. After 36 hours of therapy the following results were obtained – decrease in: fibrinogen levels (9% fall), plasminogen (40% decrease), α₂-macroglobulin (9% decrease, but no change during the first 12 hours) and fast acting α₂-antiplasmin (60% decrease); bidimensional electrophoresis consistently revealed 2 spikes during treatment: the first corresponded to complexed plasmin-fast acting α₂-antiplasmin, the second corresponded to free, unconsumed fast acting α₂-antiplasmin. Levels of α₁-antitrypsin increased by 20% whereas the antithrombin III level remained stable. FDP levels increased slightly. Recalcified plasma coagulation times progressively increased.

Therapeutic results were evaluated on phlebography and showed, after 48 hours urokinase administration, improvement in 6 patients and no improvement in 17 cases. Consumption of plasminogen and production of FDP were both greater in the improved patient group.

The authors discuss these results and suggest that the dosage level of urokinase used in this study should be modified; it is concluded that a therapeutic regimen associating a loading dose with higher hourly administration levels is needed to achieve neutralization of fast acting α₂-antiplasmin, a prerequisite to development of thrombolytic activity.

• References

• 1 Amery A, Donati MB, Vermylen J, Verstraete M. 1970; Comparison between the changes in the plasma fibrinogen and plasminogen level, induced by moderate or high initial dose of streptokinase. Thrombosis et Diathesis Haemorrhagica 23: 504
• 2 Aoki N, Moroi M, Matsuda M, Tachiya K. 1977; The behaviour of ±₂ plasmin inhibitor in fibrinolytic states. Journal of Clinical Investigation 60: 361
• 3 Arnesen H, Fagerhol MK. 1972; ±₂ macroglobulin, antitrypsin and antithrombin III in plasma and serum during fibrinolytic therapy with urokinase. Scandinavian Journal of Clinical Laboratory Investigation 29: 259
• 4 Brochier M, Fauchier JP, Griguer P, Raynaud PH, Charbonnier B, Latour F, Lavigne G, Pellois A. 1976; Le traitement thrombolytique de l’embolie pulmonaire. A propos de 80 cas traités par urokinase Angéiologie 6: 299
• 5 Clauss A. 1975; Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematologica (Basel) 17: 237
• 6 Collen D, Decock F, Edy J. 1976; Identification and some properties of a new post reacting plasmin inhibitor in human plasma. European Journal of Biochemistry 69: 209
• 7 Collen D, Nauwelaers F, Wiman B. 1978. Isolation and partial characterization of antiplasmin, the fast reacting plasmin inhibitor of human plasma. In Progress in chemical fibrinolysis and thrombolysis. Vol. 3. Raven press; New York: p 243
• 8 Courbier R, Vairel E, Brunel-Atlan F. 1969; Contrôle de la plasminémie dans la coagulation en chirurgie artérielle. Agressologie 10: 493
• 9 Duckert F, Muller C, Nyman D, Benz A, Prisender S, Madar G, Da Silva NA, Wedmer LK, Schmitt ME. 1975; Treatment of deep vein thrombosis with streptokinase. British Medical Journal 1: 479
• 10 Edy J, Collen D, Verstraete M. 1978. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S. 2251. In Progress in chemical fibrinolysis and thrombolysis, vol. 3. Raven press; New York: p 315
• 11 Fisher M. 1971; Influence of thrombolytic therapy on human antiplasmins. Thrombosis et Diathesis Haemorrhagica 47 suppl 153
• 12 Hulme B, Pitcher PM. 1973; Rapid latex screening test for detection of fibrin fibrinogen degradation products in urine after renal transplantation. Lancet 1: 6
• 13 Laurell CB. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 15: 45
• 14 Lellouch J, Lazar P. 1974; Méthodes statistiques en expérimentation biologique. Flammarion edit. Orleans p 135
• 15 Moroi M, Aoki N. 1976; Isolation and characterization of α₂ plasmin inhibitor from human plasma. The Journal of Biological Chemistry 251: 5956
• 16 Mullertz S. 1978. Natural inhibitors of fibrinolysis. In Progress in chemical fibrinolysis and thrombolysis, vol. 3. Raven press; New York: p 213
• 17 Nilehn JE, Ganrot PO. 1967; Plasmin, plasmin inhibitors and degradation products of fibrinogen in human serum during and after intravenous infusion of streptokinase. Scandinavian Journal of Clinical Laboratory Investigation 20: 113
• 18 Odegard OR, Lie M, Abildgaard U. 1975; Heparin cofactor activity measured with an amidolytic method. Thrombosis Research 6: 287
• 19 Samama M, Conard J. 1974. Surveillance biologique des traitements thrombolytiques par la streptokinase. Journées Angéiologiques de langue fran�aise L’expansion scientifique française Edit. Paris: p 48
• 20 Samama M, Conard J. 1977. Biological results during urokinase therapy at different doses. in Thrombosis and urokinase. PAOLETTI-SCHERRY Edit. Academic Press; London: p 243
• 21 Schwartz D. 1972 Méthodes statistiques à Vusage des médecins et des biologistes. Flammarion Edit. Orléans
• 22 Soria J, Soria C, Samama M. 1976; Dosage du plasminogène à l’aide d’un substrat chromogène tripeptidique. Pathologie et Biologie 24: 710
• 23 Storiko K. 1968; Normal values for 23 different human plasma proteins determined by single radial immunodifusion. Blut 16: 200
• 24 Teger-Nilson AC, Friberger P, Gysander E. 1978. Antiplasmin determination by means of a chromogenic tripeptide substrate. In Progress in chemical fibrinolysis and thrombolysis. Vol. 3. Raven press; New York: p 305